(Reuters) - In his fourth letter to Bioenvision, Steven Rouhandeh said he and his SCO Capital Partners investment vehicle still opposed the deal, since it did not reflect "the true value of Bioenvision and the clofarabine franchise."
Read more at Reuters.com Government Filings News
Read more at Reuters.com Government Filings News
No comments:
Post a Comment